A new biomarker for lung metastasis in non-seminomatous testicular cancer: De Ritis Ratio

Abstract

Purpose We aimed to show that the De Ritis Ratio (DRR) may be a new biomarker for lung metastasis in non-seminomatous Testicular Cancers (TC).

Material and Methods Patients who underwent radical orchiectomy due to TC between January 2010 and January 2021 were included in the study. Demographic characteristics, preoperative laboratory and radiological findings and pathological data of the patients were recorded. The DRR was calculated from preoperative peripheral blood analysis.

Results A total of 124 patients with non-seminomatous TC were included. Mean patient age was 30.67±7.45 years, and the mean tumour diameter was 4.69±2.55 cm. 61 patients had T1, 51 had T2, and 12 had T3 disease. 42 of them had lung metastasis; 82 of them had no lung metastasis. The optimal DRR threshold was 1.21 for lung metastasis. [Area Under the Curve (AUC): 0.724 with a sensitivity of 81% and specificity of 74%]. DRR was determined as an independent prognostic factor for lung metastasis in univariate and multivariate analyses (p=0.002).

Conclusions A high preoperative DRR can be used to detect the presence of lung metastases in non-seminomatous TCs.

Zusammenfassung

Unser Ziel war es zu zeigen, dass De Ritis Ratio ein neuer Biomarker für Lungenmetastasen bei nicht-seminomatösem Hodenkrebs sein könnte. Patienten, die sich zwischen Januar 2010 und Januar 2021 einer radikalen Orchiektomie aufgrund von Hodenkrebs unterzogen hatten, wurden in die Studie eingeschlossen. Demografische Merkmale, präoperative Labor- und radiologische Befunde sowie pathologische Daten der Patienten wurden erfasst. Die De Ritis Ratio wurde aus der präoperativen peripheren Blutanalyse berechnet. Insgesamt wurden 124 Patienten mit nicht-seminomatösem Hodenkrebs eingeschlossen. Das Durchschnittsalter der Patienten betrug 30,67 ± 7,45 Jahre und der mittlere Tumordurchmesser 4,69 ± 2,55 cm. 61 Patienten hatten eine T1-, 51 eine T2-, 12 eine T3-Erkrankung. 42 von ihnen hatten Lungenmetastasen, 82 von ihnen hatten keine Lunge Metastasierung.

Der optimale De-Ritis-Ratio-Schwellenwert lag bei 1,21 für Lungenmetastasen. [Fläche unter der Kurve (AUC): 0,724 mit einer Sensitivität von 81% und einer Spezifität von 74%]. De Ritis Ratio wurde als unabhängiger Prognosefaktor für Lungenmetastasen in univariaten und multivariaten Analysen ermittelt (p=0,002).

Die präoperative hohe De Ritis Ratio kann verwendet werden, um das Vorhandensein von Lungenmetastasen bei nicht-seminomatösem Hodenkrebs nachzuweisen.

Schlüsselwörter

Hodenkrebs - De Ritis Ratio - Lungenmetastasen - Aspartat-Aminotransferase - Alanin-Aminotransferase

Keywords

testicular cancer - lung metastasis - aspartate aminotransferase - alanin aminotransferase - De Ritis ratio

Publication History

Received: 03 July 2022

Accepted: 14 August 2022

Article published online:
27 October 2022

• References

• 1 La Vecchia C. et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 2010; 21: 1323-1360 DOI: 10.1093/annonc/mdp530. (PMID: 19948741)
• 2 Jemal A. et al. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
• 3 Nigam M, Aschebrook-Kilfoy B, Shikanov S. et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J. Urol 2015; 33: 623-631 DOI: 10.1007/s00345-014-1361-y. (PMID: 25030752)
• 4 Williamson SR. et al. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 2017; 70: 335-346 DOI: 10.1111/his.13102. (PMID: 27747907)
• 5 Angulo JC. et al. Clinicopathological Study of Regressed Testicular Tumors (Apparent Extragonadal Germ Cell Neoplasms). J Urol 2009; 182: 2303-2310
• 6 Gilligan TD. et al. American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. J. Clin. Oncol 2010; 28: 3388-3404
• 7 De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis: The transaminase serum activities. Clin Chim 1957; Acta 2: 70-74
• 8 Kang M. et al. Clinical Significance of Pre-to-Postoperative Dynamics of Aspartate Transaminase/Alanine Transaminase Ratio in Predicting the Prognosis of Renal Cell Carcinoma after Surgical Treatment. Dis Markers 2020; 6702964
• 9 Yuk HD, Jeong CW, Kwak C. et al. De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study . Dis. Markers 2019; 6702964
• 10 Zhou J, He Z, Ma S. et al. AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer. Cancer Med 2020; 9: 5672-5677 DOI: 10.1002/cam4.3086. (PMID: 32562455)
• 11 Li Y. et al. High aspartate transaminase/alanine transaminase ratio predicts poor prognosis in patients with localized upper tract urothelial cancer: a propensity score-matched study in a large Chinese center. Onco Targets Ther 2019; 12: 2635-2648 DOI: 10.2147/OTT.S193771. (PMID: 31114222)
• 12 Ling H, Krassnig L, Bullock MD. et al. MicroRNAs in Testicular Cancer Diagnosis and Prognosis. Urol Clin North Am 2016; 43: 127-134 DOI: 10.1016/j.ucl.2015.08.013. (PMID: 26614035)
• 13 Bezan A, Gerger A, Pichler M. MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2014; 34: 2709-13 (PMID: 24922631)
• 14 Mead GM, Stenning SP. The international germ cell consensus classification: A new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol 1997; 9: 207-209 DOI: 10.1016/s0936-6555(97)80001-5. (PMID: 9315391)
• 15 Guner E. et al. The utility of De Ritis Ratio in predicting prognosis in testicular cancer. Aktuelle Urol 2020; 51: 285-289 DOI: 10.1055/a-1117-2776. (PMID: 32135561)
• 16 Gorgel SN. et al. Impact of increased aspartate aminotransferase to alanine aminotransferase (De Ritis) ratio in prognosis of testicular cancer. Investig Clin Uro 2019; 60: 169
• 17 Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev 2013; 34: 117-30 (PMID: 24353357)
• 18 Warburg O. On the Origin of Cancer Cells. Science (80-.) 1956; 123: 309-314
• 19 Kato Y, Xy X. et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int 2013; 13: 89 DOI: 10.1186/1475-2867-13-89. (PMID: 24004445)
• 20 Vander Heiden MG, Cantley LC, Thompson C B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science (80-.) 2009; 324: 1029-1033
• 21 DeBerardinis RJ. et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci 2007; 104: 19345-19350
• 22 Yang C. et al. Glioblastoma Cells Require Glutamate Dehydrogenase to Survive Impairments of Glucose Metabolism or Akt Signaling. Cancer Res 2009; 69: 7986-7993
• 23 Elf SE, Chen J. Targeting glucose metabolism in patients with cancer. Cancer 2014; 120: 774-780 DOI: 10.1002/cncr.28501. (PMID: 24374503)
• 24 Blay J-Y. et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72: 424-430
• 25 Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011; 11: 85-95 DOI: 10.1038/nrc2981. (PMID: 21258394)